Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04511013
Title A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Southwest Oncology Group
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Binimetinib + Encorafenib + Nivolumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST